Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the ...

An announcement from Neurocrine ( (NBIX)) is now available. On January 24, 2025, Neurocrine Biosciences announced an amendment to its Exclusive License Agreement with Takeda Pharmaceutical ...

Neurocrine Biosciences (NBIX) announced it has amended its agreement with Takeda (TAK) to develop and commercialize osavampator. Under the amended agreement, Neurocrine will obtain exclusive ...

Neurocrine Biosciences exceeded earnings expectations ... in its pipeline and strategic collaborations with firms like Takeda. Ingrezza's success and ongoing innovation in R&D are fundamental ...

Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.

Also Read: Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights Ingrezza fourth-quarter net product sales grew 23% compared to fourth quarter 2023, driven by ...

Neurocrine's Phase 3 pipeline is also set to ... we have that came out of the Phase 2 program and quite frankly, so was Takeda. As we've seen from Takeda over the past several years, they've ...

Neurocrine Biosciences stock is a buy due to robust sales growth, augmented by the FDA approval of CRENESSITY in December 2024. INGREZZA dominates current sales, but CRENESSITY, a new treatment ...

Stifel analysts have maintained a positive outlook on the company's stock, following an amendment to Neurocrine's partnership with Takeda on the AMPA program, allowing Neurocrine full worldwide ...